About GSK

£7.2bn, +19% CER sales turnover 2019

Our Vaccines business has a broad portfolio and innovative pipeline of vaccines to help protect people throughout life. We deliver over two million vaccine doses per day to people living in over 160 countries. 

Key products
Shingrix – Shingles
Infanrix – Paediatric
Bexsero – Meningitis

£9bn, +17% CER sales turnover 2019 (Pro-forma +2% CER*)

Our Consumer Healthcare business develops and markets an innovative portfolio of consumer preferred and expert recommended brands in the Pain relief, Respiratory, Digestive health, Oral health, Nutrition and Skin health categories.

On 1 August 2019 we announced that we'd completed our transaction with Pfizer to combine our consumer healthcare businesses into a new world-leading Consumer Healthcare Joint Venture. Within three years of the closing of the transaction, we intend to separate the Joint Venture via a demerger. With our future intention to separate, the transaction also presents a clear pathway forward for us to create a new global Pharmaceuticals/Vaccines company, and a new world-leading Consumer Healthcare company. Find out more

Key products
Sensodyne – Oral health
Voltaren – Pain relief (topical)
Panadol – Pain relief (systemic)

*Reported AER and CER growth rates include five months’ results of former Pfizer consumer healthcare business. Pro-forma CER growth rates are calculated as if the equivalent five months of Pfizer consumer healthcare business results, as reported by Pfizer, were included in the comparative period of 2018.